-
Purposemammalian expression of ALK3 WT
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 80873 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepcDNA3
-
Vector typeMammalian Expression
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameALK3
-
Alt nameBMPR1A
-
Alt namebone morphogenetic protein receptor type 1A
-
SpeciesH. sapiens (human)
-
Entrez GeneBMPR1A (a.k.a. 10q23del, ACVRLK3, ALK-3, ALK3, BMPR-1A, CD292, SKR5)
- Promoter CMV
-
Tag
/ Fusion Protein
- HA (C terminal on backbone)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site EcoRI (not destroyed)
- 3′ cloning site XhoI (not destroyed)
- 5′ sequencing primer CMV-F
- 3′ sequencing primer BGH-rev (Common Sequencing Primers)
Resource Information
-
Articles Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
This plasmid contains a P2A mutation compared to NM_004329.2 and SL insertion after the c-terminal HA tag. The depositor states that these discrepancies do not affect plasmid function.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pcDNA3-ALK3 wt was a gift from Aristidis Moustakas (Addgene plasmid # 80873 ; http://n2t.net/addgene:80873 ; RRID:Addgene_80873) -
For your References section:
The protein kinase LKB1 negatively regulates bone morphogenetic protein receptor signaling. Raja E, Tzavlaki K, Vuilleumier R, Edlund K, Kahata K, Zieba A, Moren A, Watanabe Y, Voytyuk I, Botling J, Soderberg O, Micke P, Pyrowolakis G, Heldin CH, Moustakas A. Oncotarget. 2016 Jan 12;7(2):1120-43. doi: 10.18632/oncotarget.6683. 10.18632/oncotarget.6683 PubMed 26701726